Ascendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $160.00 at TD Cowen

Ascendis Pharma A/S (NASDAQ:ASND) had its price target hoisted by TD Cowen from $157.00 to $160.00 in a research note issued to investors on Monday, Benzinga reports. TD Cowen currently has a buy rating on the biotechnology company’s stock.

A number of other equities analysts also recently commented on the company. Bank of America lifted their target price on Ascendis Pharma A/S from $175.00 to $191.00 and gave the company a “buy” rating in a research note on Monday, September 23rd. StockNews.com upgraded Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Thursday, September 5th. Evercore ISI increased their target price on Ascendis Pharma A/S from $191.00 to $205.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 17th. Citigroup boosted their price target on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the company a “buy” rating in a report on Tuesday, September 17th. Finally, The Goldman Sachs Group increased their price objective on shares of Ascendis Pharma A/S from $180.00 to $200.00 and gave the stock a “buy” rating in a report on Tuesday, September 17th. Two analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $195.92.

Ascendis Pharma A/S Trading Down 1.1 %

ASND stock opened at $127.69 on Monday. The firm has a market cap of $7.44 billion, a P/E ratio of -13.29 and a beta of 0.64. The stock’s 50 day simple moving average is $135.09 and its 200 day simple moving average is $134.69. Ascendis Pharma A/S has a 12-month low of $85.38 and a 12-month high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). The firm had revenue of $38.75 million for the quarter, compared to the consensus estimate of $94.74 million. On average, research analysts forecast that Ascendis Pharma A/S will post -7.2 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Private Ocean LLC acquired a new stake in shares of Ascendis Pharma A/S during the 1st quarter valued at $36,000. GAMMA Investing LLC lifted its holdings in shares of Ascendis Pharma A/S by 52.0% during the first quarter. GAMMA Investing LLC now owns 298 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 102 shares during the last quarter. Signaturefd LLC boosted its position in shares of Ascendis Pharma A/S by 13.2% in the 3rd quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock valued at $102,000 after purchasing an additional 80 shares during the period. Bessemer Group Inc. increased its stake in Ascendis Pharma A/S by 61.0% in the 1st quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company’s stock worth $132,000 after purchasing an additional 332 shares in the last quarter. Finally, Searle & CO. purchased a new position in Ascendis Pharma A/S in the 2nd quarter worth about $205,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.